Barclays Reaffirms Their Sell Rating on Lifestance Health Group (LFST)

Barclays analyst Stephanie Davis maintained a Sell rating on Lifestance Health Group (LFST – Research Report) today and set a price target of $8.00. The company’s shares closed yesterday at $7.12.

According to TipRanks, Davis is an analyst with an average return of -7.1% and a 39.67% success rate. Davis covers the Healthcare sector, focusing on stocks such as Healthequity, Health Catalyst, and Laboratory.

Currently, the analyst consensus on Lifestance Health Group is a Hold with an average price target of $8.92.

Based on Lifestance Health Group’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $280.6 million and a GAAP net loss of $44.96 million. In comparison, last year the company earned a revenue of $229.36 million and had a GAAP net loss of $46.66 million

Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LFST in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Lifestance Health Group (LFST) Company Description:

LifeStance Health Group Inc is a providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. The company delivers personalized, data-driven and comprehensive care to help patients stay healthy and employs over 3,300 psychiatrists, advanced practice nurses, psychologists and therapists.